TY - JOUR
T1 - Myelodysplastic Syndromes, Version 3.2022
T2 - Featured Updates to the NCCN Guidelines
AU - Greenberg, Peter L.
AU - Stone, Richard M.
AU - Al-Kali, Aref
AU - Bennett, John M.
AU - Borate, Uma
AU - Brunner, Andrew M.
AU - Chai-Ho, Wanxing
AU - Curtin, Peter
AU - De Castro, Carlos M.
AU - Joachim Deeg, H.
AU - DeZern, Amy E.
AU - Dinner, Shira
AU - Foucar, Charles
AU - Gaensler, Karin
AU - Garcia-Manero, Guillermo
AU - Griffiths, Elizabeth A.
AU - Head, David
AU - Jonas, Brian A.
AU - Keel, Sioban
AU - Madanat, Yazan
AU - Maness, Lori J.
AU - Mangan, James
AU - McCurdy, Shannon
AU - McMahon, Christine
AU - Patel, Bhumika
AU - Reddy, Vishnu V.
AU - Sallman, David A.
AU - Shallis, Rory
AU - Shami, Paul J.
AU - Thota, Swapna
AU - Varshavsky-Yanovsky, Asya Nina
AU - Westervelt, Peter
AU - Hollinger, Elizabeth
AU - Shead, Dorothy A.
AU - Hochstetler, Cindy
N1 - Publisher Copyright:
© 2022 Harborside Press. All rights reserved.
PY - 2022/2
Y1 - 2022/2
N2 - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
AB - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
UR - http://www.scopus.com/inward/record.url?scp=85124256299&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.0009
DO - 10.6004/jnccn.2022.0009
M3 - Article
C2 - 35130502
AN - SCOPUS:85124256299
SN - 1540-1405
VL - 20
SP - 106
EP - 117
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
ER -